Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi-Aventis, Merrimack Enter MAb Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Sanofi-Aventis, Merrimack Enter MAb Pact

Merrimack Pharmaceuticals, Inc. and Sanofi-Aventis signed an exclusive worldwide licensing agreement for the development and commercialization of MM-121, a fully human monoclonal antibody designed to block signaling of the ErbB3 receptor.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merrimack Pharmaceuticals, Inc. and Sanofi-Aventis signed an exclusive worldwide licensing agreement for the development and commercialization of MM-121, a fully human monoclonal antibody designed to block signaling of the ErbB3 receptor. MM-121 is currently in Phase I testing as a potential treatment for cancer.

SA will make an upfront payment of $60 million and will be responsible for all development costs. Merrimack is eligible for an additional $470 million in milestone payments as well as royalties on sales. Merrimack will develop MM-121 through Phase II for each indication and SA will be responsible for further development. Merrimack retains the right to co-promote the therapy in the U.S.

The ErbB3 receptor is a novel target known to be a key mediator of a signaling network that impacts a broad array of cancers. By targeting ErbB3, MM-121 is believed to have a broad application across cancer as both a monotherapy and in combination with other therapeutics.

“Merrimack’s expertise along with their knowledge of biologics development has allowed them to successfully identify ErbB3 as a promising target and rapidly bring MM-121 into clinical development,” said Marc Cluzel, senior vice president R&D, SA. “MM-121 is a pioneering monoclonal antibody which brings a new innovative approach to Sanofi-Aventis’ oncology portfolio. We are very excited to collaborate with Merrimack on the development of MM-121, which we believe is a very promising compound that will address a significant gap in treating cancer patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters